Novo Nordisk and Eli Lilly rival soars 35% after promising weight loss drug results
Publishing timestamp: 2024-02-26 11:45:26
Summary
Zealand Pharma's shares surged 35% after successful trial results for its liver disease treatment, which is also being tested as a weight loss drug. Analysts are optimistic about the company's potential in the obesity market, with other pharmaceutical companies also vying to enter the space.
Sentiment: POSITIVE
Tickers: ZEAL-DK, LLY, 0NZU-GB?QSEARCHTERM=, NOVO.B-DK,
Keywords: breaking news: markets, markets, eli lilly and co, zealand pharma a/s, pharmaceuticals, novo nordisk a/s, health care industry, business news,